WeVote
Log In

Bill

Bill

HF 2230

All pharmacies required to make ivermectin and hydroxychloroquine available without a prescription.

2025-2026 Regular Session Introduced by Pam Altendorf and 5 co-sponsors

The bill would require all Minnesota pharmacies to stock and provide ivermectin and hydroxychloroquine without a prescription.

Author added Schultz
#drugsandmedicine #healthandhealthdepartment
0
WeVote Research Nonpartisan
Bill Summary · HF 2230

Summary of HF 2230 (2025-2026) — Minnesota

Overview

HF 2230 is a bill introduced in the Minnesota Legislature that would require all pharmacies in the state to make ivermectin and hydroxychloroquine available without a prescription. The bill is authored in the 2025-2026 session and has several co-sponsors. It was introduced and referred to Health Finance and Policy in March 2025.

Sponsorship

  • Primary sponsors and co-sponsors include:
    • Jim Joy (co-sponsor)
    • Shane Mekeland (co-sponsor)
    • Pam Altendorf (co-sponsor)
    • Isaac Schultz (co-sponsor)
    • John Burkel (co-sponsor)
    • Krista Knudsen (co-sponsor)

Purpose and Intent

  • The bill aims to remove prescription requirements for two drugs—ivermectin and hydroxychloroquine—by mandating that all pharmacies in Minnesota stock and provide these medications without a prescription.

Key Provisions (high-level)

  • Repeal or modification of prescription requirements: The central provision would authorize over-the-counter access to ivermectin and hydroxychloroquine at every pharmacy in the state.
  • Accessibility mandate for pharmacies: Pharmacies would be required to ensure these drugs are available to customers without needing a physician’s prescription.
  • Scope of coverage: The measure applies to all pharmacies operating within Minnesota.

Who/What is Affected

  • Primary affected entities:
    • All pharmacies licensed and operating in Minnesota.
  • Indirectly affected:
    • Consumers seeking ivermectin and hydroxychloroquine without a prescription.
    • Healthcare providers and prescribers, who would no longer need to issue prescriptions for these drugs to enable access at a pharmacy.

Procedural and Timeline Aspects

  • Introduction and first reading: March 12, 2025, with referral to Health Finance and Policy.
  • Action history shows additional sponsor additions on April 21, 2025.
  • As of the available record, the bill had not progressed beyond committee referral, so substantive provisions and timeline for enactment (e.g., compliance deadlines, enforcement mechanisms) are not specified in the provided notes.

Potential Implications

  • Public Health and Safety: Making prescription medications available over the counter could impact use patterns, monitoring, and adverse event reporting. Without prescription controls, there may be concerns about dosing guidance, drug interactions, and appropriate indications.
  • Regulatory and Oversight: The bill would shift certain regulatory responsibilities from prescribers and pharmacists to a broader over-the-counter framework, potentially raising questions about labeling, pharmacist counseling, and pharmacist liability.
  • Access and Equity: Proponents may argue it improves access for individuals lacking timely medical care or prescription access; opponents may raise concerns about inappropriate use or self-medication.

Note

  • The summary reflects the bill text and public action history as of the provided record. For a complete understanding, review the full bill language, fiscal impact statements, and any subsequent committee amendments or floor actions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.